Cell-cell adhesion regulates Merlin/NF2 interaction with the PAF complex

Anne E. Roehrig¹*, Kristina Klupsch¹*, Juan A. Oses-Prieto², Selim Chaib¹, Stephen Henderson¹, Warren Emmett³, Lucy C. Young¹, Silvia Surinova¹, Andreas Blees¹, Anett Pfeiffer¹, Maha Tijani¹, Fabian Brunk¹, Nicole Hartig¹, Marta Muñoz-Alegre¹, Alexander Hergovich¹, Barbara H. Jennings¹, Alma L. Burlingame², Pablo Rodriguez-Viciana¹*

¹ UCL Cancer Institute, University College London, London, United Kingdom, ² Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, United States of America, ³ University College London Genet ics Institute, London, United Kingdom

☯ These authors contributed equally to this work.
* p.rodriguez-viciana@ucl.ac.uk

Abstract

The PAF complex (PAFC) coordinates transcription elongation and mRNA processing and its CDC73/parafibromin subunit functions as a tumour suppressor. The NF2/Merlin tumour suppressor functions both at the cell cortex and nucleus and is a key mediator of contact inhibition but the molecular mechanisms remain unclear. In this study we have used affinity proteomics to identify novel Merlin interacting proteins and show that Merlin forms a complex with multiple proteins involved in RNA processing including the PAFC and the CHD1 chromatin remodeller. Tumour-derived inactivating mutations in both Merlin and the CDC73 PAFC subunit mutually disrupt their interaction and growth suppression by Merlin requires CDC73. Merlin interacts with the PAFC in a cell density-dependent manner and we identify a role for FAT cadherins in regulating the Merlin-PAFC interaction. Our results suggest that in addition to its function within the Hippo pathway, Merlin is part of a tumour suppressor network regulated by cell-cell adhesion which coordinates post-initiation steps of the transcription cycle of genes mediating contact inhibition.

Introduction

Normal cells cease to proliferate when they come into contact with each other and assemble intercellular junctions. Contact-dependent inhibition of proliferation is essential for normal tissue homeostasis and its loss is one of the hallmarks of cancer [1, 2]. The molecular mechanisms underlying contact inhibition remain unclear but Merlin, the protein encoded by the NF2 tumour suppressor gene is known to be an important mediator [3].

Germline mutations in NF2 cause Neurofibromatosis type 2, a cancer syndrome characterized by the development of schwannomas, meningiomas and ependymomas. Somatic NF2 mutations are frequently found in these tumour types as well as at lower frequency in several others [3–5].
Merlin functions as an upstream regulator of the Hippo tumour suppressor pathway to inactivate the YAP/TAZ transcriptional co-activators [6–8]. In the absence of Hippo signalling, YAP/TAZ translocate to the nucleus to promote transcription of genes that regulate tissue homeostasis, organ size and tumorigenesis [9]. Merlin has also been implicated in controlling the surface availability of membrane receptors and in the regulation of multiple signalling pathways [10].

Merlin can localize to different cellular compartments. It is found at the cell cortex in lamellipodia and membrane ruffles and at cell–cell contacts in dense cultures where it can interact with α-catenin and Par3 at nascent adherens junctions and with Angiomotin/AMOT at tight junctions [11, 12]. Merlin can also exhibit a punctate distribution that has been attributed to intracellular vesicles or particles that can move along microtubules in a kinesin and dynein-dependent manner [13–15]. In addition, Merlin can also localize to the nucleus in a density and cell cycle dependent manner [16–20].

Transcription of mRNAs is a tightly regulated process consisting of discrete stages of RNA polymerase II (Pol II) recruitment, initiation, elongation and termination. Transcription elongation is recognized to play a key role in regulated gene expression. In particular, promoter-proximal pausing of Pol II and its release to initiate productive elongation are key regulatory steps in transcription with its precise intensity and the mechanisms regulating pause release likely varying from gene to gene [21–23]. After promoter-proximal pause release, elongation rates also vary between genes and are closely linked to co-transcriptional RNA processing steps such as splicing, cleavage and polyadenylation [23]. Chromatin represents a barrier to transcription by Pol II that has to be overcome as well as restored following polymerase passage. Accordingly, elongation is also tightly coupled with modulation of chromatin structure through the concerted actions of chromatin remodelers, histone-modifying enzymes and histone chaperones [24].

The Pol II-associated factor 1 complex (PAFC) has been linked to multiple transcription related processes including communicating with transcriptional activators, recruiting histone modification factors, release from promoter-proximal pausing, facilitating elongation across chromatin templates, recruitment of 3’ end processing factors and mRNA stability [25–29]. In humans it is composed of 5 subunits, PAF1, CTR9, LEO1, CDC73 and SKI8. CDC73, also called Parafibromin, is inactivated in Hyperparathyroidism-jaw tumour (HPT-JT) syndrome, an autosomal dominant disorder characterized by the development of parathyroid tumours as well as uterine and renal cancers. [30]. The PAF1 subunit localizes to 19q13, a locus amplified in several tumours and has transforming properties highlighting a role for the PAFC in cancer [31].

In this study we show that Merlin interacts with multiple proteins involved in transcription elongation and/or mRNA processing including the PAFC, the CHD1 chromatin remodeler and the TAT-SF1 elongation/splicing factor. We use genomics to identify Merlin-regulated genes and proteomics to show Merlin can regulate the PAFC interactome and identify an interaction between CDC73 and FAT cadherins that is required for Merlin interaction with the PAFC. Our results suggest that in addition to its role within the Hippo pathway, Merlin is part of a tumour suppressor network which helps regulate expression of genes mediating contact inhibition by coordinating initiation and post-initiation steps of their transcription cycle in response to cell adhesion.

**Materials and methods**

**Antibodies and constructs**

AMOTL1 (HPA001196), Flag (M2), FAT1 (HPA001869) and HA-peroxidase antibodies were obtained from Sigma. Merlin (E-2 and A-19), RNA Pol2 (N-20), SPT16 (H-4), HA (Y-11), MYC (A-14) and anti-goat-HRP (sc-2020) antibodies from Santa Cruz and p21 (05–345) from
Millipore, AMOT (303A), CDC73 (170A), CHD1 (218A), CTR9 (395A), DDB1 (462A), LEO1 (175A), Merlin iso1 (A578), Merlin iso2 (A579), PAF1 (172A), PELP1 (180A), RTF1 (179A), YAP (309A), SF3A3 (507A), SF3B1 (997A), SF3B3 (508A), TAT-SF1 (023A), VPRBP (887A and 888A), FAT1 (402A and 403A) antibodies were from Bethyl Laboratories, FLAG-Dy-light680 and HA-IRDye800 from rockland. Anti-mouse-HRP (NA 931) and anti-rabbit-HRP (NA934) were obtained from Amersham. cDNAs were cloned into the pENTR vector (Invitrogen) and transferred to Gateway-compatible expression vectors using recombination-mediated Gateway technology (Invitrogen). Mutations were generated using the QuikChange site-directed mutagenesis kit (Stratagene).

**Cell culture and virus generation**

Dulbecco’s Modified Eagle’s Medium (DMEM) and Roswell Park Memorial Institute (RPMI) Medium was supplemented with 10% FBS; DMEM F12 was supplemented with 5% HS, 20 ng/ml EGF, 0.5 μg/ml hydrocortisone, 100 ng/ml cholera toxin and 10 μg/ml insulin. All cells were grown in DMEM except for 786–0, 8505C, ACHN, B-CPAP, CAKI-1, CGTH-W-1, S-117 and SN12C which were grown in RPMI, and HMLE and MCF10A which were grown in DMEM F12. Lentiviruses were generated by transient transfection of HEK293T cells with the lentiviral construct, pMD.G (VSV-G) and p8.91 (gag-pol) packaging vectors. Virus-containing medium was harvested 48 h and 72 h after transfection and supplemented with 5 μg/ml Polybrene (hexadimethrine bromide, Sigma-Aldrich). Cells were transduced with lentivirus and selected 24 hours later with 2.5 mg/ml puromycin (Sigma-Aldrich) or 10 mg/ml Blasticidin (Melford). Retroviruses were generated by transient transfection of the Phoenix ecotropic cell line and virus was collected and cells infected as above. Cell lines expressing the ecotropic receptor EcoR were generated by transduction with amphotropic EcoR retroviruses and selection with Blasticidin. Retroviruses and lentiviruses were titered by infection with serial dilutions in HEK293T and/or IOMM-Lee cells.

**Transfections**

2x10^6 HEK293T cells were transfected with 2ug plasmid DNA and 1 mg/ml polyethylenimine (PEI, Polysciences) mixed at a 1:5 ratio in OptiMEM (Gibco). After 30 min incubation at RT the transfection solution was added to cells seeded 2 h prior. Fresh medium was added 16–24 h after transfection and cells harvested the day after. For RNAi knockdown experiments cells were seeded 2 h prior transfection using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s recommendations using 10 nM siRNA oligos and lysed 3 days later. Stealth RNAi Negative Control Medium GC Duplex (Invitrogen) was used as control oligo. Stealth siRNA oligos were from Invitrogen and are listed below. Smartpools were obtained from Thermo Scientific. **Purification of recombinant proteins and ‘Fishing’ experiments**

Baculoviruses expressing Merlin wild type and variants expressed as GST-fusions proteins were generated using the FastBac method (Invitrogen). 3 days after infection, Sf9 cells were lysed in PBS-E LB and clarified lysates purified with Gluthathione Sepharose beads as above. After extensive washing, beads and bound proteins were stored in 50% glycerol at -20°C. 10 μl of beads were added to lysates, incubated for 2 h, washed and eluted with LDS sample buffer. Co-purifying proteins were detected by Western blotting with the appropriate antibodies.

**Nuclear fractionation/ enrichment**

HT-1080 fibrosarcoma cells were infected with lentiviruses expressing shRNA hairpins targeting non-silencing control, NF2, VPRBP or PELP1 and selected in 2.5 μg/ml puromycin. shRNAmir sequences were from pGIPZ library (Open Biosystems):
Non-silencing: CTCTCGTGGGGCGAGAGTAAG
NF2-1: CCGGGTGAATCTTTTCGAAT
NF2-3: CGCAGCAAGCACAATACCATTA
VPRBP: CGCACTTCAGATTATCATCAAT
PELP1: AAGGATTTGACAGTTATTAATA.

Cells were washed twice with cold PBS, washed once quickly with hypotonic buffer without Triton X-100 and lysed in hypotonic buffer (20 mM Hepes (pH 7.5), 10 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 0.1% (v/v) Triton X-100, 20% Glycerol (v/v)) on ice for 10 min. Cells were scraped and spun at 150 g for 10 min at 4˚C. The supernatant was kept as the cytosolic fraction. The nuclear pellet was washed once in hypotonic buffer without Triton X-100 but supplemented with 1 mM DTT, phosphatase inhibitor (Halt, Thermo Scientific) and protease inhibitor (Roche) and lysed in 5x pellet volume of hypertonic buffer (20 mM Hepes (pH 7.5), 0.5 M NaCl, 1.5 mM MgCl2, 1 mM EDTA, 20% Glycerol (v/v)) for 30 min at 4˚C. The lysate was subsequently spun at 16000 g for 10 min. The supernatant yielded the nuclear fraction. The pellet was lysed in 20 μl 2x LDS for nuclear insoluble fraction.

Interaction assays
Cells were lysed in PBS-E LB (1x PBS, 1% TX100, 1 mM EDTA, 1 mM DTT, Protease Inhibitor cocktail (Roche) and Phosphatase Inhibitor solution (Sigma)). When indicated RIPA buffer (PBS-E LB+ 0.1% SDS, 0.5% DOC,) was used. Flag (M2) agarose beads (Sigma-Aldrich), glutathione sepharose beads (GE Healthcare), or a combination of the appropriate antibody and Protein A or G sepharose beads (GE Healthcare) were used to immunoprecipitate tagged or endogenous proteins from cleared lysates. For cell density experiments, when 10cm dishes reached ~90% confluency, either medium was changed (Dense) or split to 4-5x15cm dishes (Sparse) and cells harvested 12–15 hrs later. Immunoprecipitates were extensively washed with lysis buffer minus inhibitors, drained and resuspended in NuPAGE LDS sample buffer (Life Technologies).

Clonogenic assays
Cells were infected with retroviruses or lentiviruses expressing either Merlin or Ezrin, seeded at different densities in 6-well plates and stained with crystal violet (0.5% in 10% Methanol) 7–14 days later when the Ezrin or empty vector control wells reached confluency.

Flow-cytometry
Cells were fixed in 70% Ethanol two days after retroviral infection with YFP-Ezrin/Merlin and cell cycle profiles assessed by propidium iodide (PI) staining. The cell cycle of YFP-positive cells is shown, no changes were seen in the YFP-negative population of cells. Where indicated cells were transfected with siRNA, infected 24 hrs later with retroviruses expressing YFP constructs and harvested 48 hrs later for FACS analysis.

Ubiquitination assays
Cells were co-transfected with pMT123-HA-ubiquitin (Treier et al., 1994) and lysed 2 days later. For denaturing conditions, cells were lysed with Guanidine lysis buffer (6M Guanidine-HCl, 50mM NaHPO4 buffer pH8, 0.3M NaCl, 0.1% TX-100, 10mM imidazole, 5mM b-Mercaptoethanol), briefly sonicated and incubated after centrifugation with TALON beads. Beads
were washed once with Guanidine LB and 3 times with Urea wash buffer (8M urea, 50mM NaHPO4 buffer pH 8, 0.3M NaCl, 0.1% TX-100, 10mM imidazole, 5mM b-Mercaptoethanol). For native conditions, cells were lysed in RIPA buffer (1x PBS, 1% TX100, 0.1% SDS, 0.5% Sodium deoxicholate, 1 mM EDTA, 1 mM DTT, with Protease and Phosphatase Inhibitors). Cleared lysates were incubated with Flag beads for 1–2 hours and beads washed 4 times with RIPA LB. Drained beads were resuspended in LDS sample buffer and run in Nupage 4–12% gels. After gel transfer, membranes were probed with anti-HA-peroxidase (Roche-12013819001) and developed by chemiluminescence or with FLAG-Dylight680 and HA-IRDye800 (Rockland) and developed with the Odyssey imaging system (Lycor).

**Gene expression analysis**

Gene expression profiles were determined using Whole-transcript Expression Analysis on GeneChip® Human Gene 2.0 ST Arrays (Affymetrix). Total RNA was extracted 48 hours after lentiviral infection using the RNeasy Mini Kit (Qiagen). cDNA was generated using the WT Expression Kit (Ambion) and labeled using the GeneChip WT Terminal Labeling Kit (Affymetrix). The hybridisation protocols were performed on GeneChip Fluidics Station 450, and scanned using the Affymetrix GeneChip Scanner. Expression data was pre-processed and normalised using ‘affy’ and the RMA algorithm [32] and differential expression determined using ‘limma’ [33]. Unless otherwise stated, significant difference of expression is taken as q < 0.05 (false discovery rate adjusted) and fold-change greater than +/- 1.5.

For qRT-PCR, RNA was reverse transcribed using Protoscript M-MuLV First Strand cDNA Synthesis Kit (New England Biolabs) and analysed by quantitative real-time PCR (qPCR) with SYBR green fluorescence. Data were normalized to Actin and GAPDH expression as indicated. See supplementary experimental procedures for primer sequences.

Microarray data has been deposited in GEO as GSE53501 and ChIP-seq. data in EMBL-EBI as SRP035339.

**ChIP-qPCR and ChIP sequencing**

Cells were infected with lentiviruses expressing Ezrin or Merlin, selected the next day with puromycin for 24 hours and fixed with 1% formaldehyde 48 hours after infection. DNA was sheared by sonication (Vibra-cell, Sonics) to an average length of 400 bp in ChIP lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0). Sheared chromatin was diluted 1/10 in ChIP IP buffer (0.1% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris-HCl, pH 8.0) and protein/DNA complexes were immunoprecipitated overnight with indicated antibodies. After extensive washing and decrosslinking DNA was purified by phenol/chloroform extraction and quantified by real-time PCR (Mastercycler ep Realplex, Eppendorf) measuring an increase in SYBR Green (Fermentas). qPCR conditions were the following: 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The amount of DNA recovered was normalized against input DNA. See below for primer sequences.

For ChIP-Sequencing cells were fixed, processed and the chromatin IPed as described above. The ChIP-seq libraries were prepared using 300ng of input DNA and ChIP DNA using the NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina (New England Biolabs). After end repair and addition of A base to 3’ ends, barcoded adaptors (Multiplex Oligos for Illumina, New England Biolabs) were ligated to DNA fragments. Following an 18 cycle PCR, DNA fragments of 150-300bp were purified by agarose gel purification. ChIP-Seq libraries were then normalised, pooled and sequenced on one lane of the HiSeq 2000 platform (Illumina) using the latest v3 reagents, at a final concentration of 12pM. Illumina’s CASAVA
software (v1.8.2) was then used to demultiplex the pooled sequence data and create fastq files for each sample.

Raw paired end Illumina data (Illumina pipeline 1.3+) was first trimmed to 50bp then aligned to the Hg19 human reference using BWA version 0.5.9 (Li and Durbin, 2010). Read counts were then generated for each gene in a sample by selecting the longest known transcript and an additional 400bp upstream of the TSS. Further processing was then undertaken using the R statistical programming language (version 2.14.2) (R Development Core Team, 2012) including the DESeq bioconductor package (version 2.11) [34].

After normalising by library size the antibody control count from each gene was deducted from each sample. Differential enrichment statistics were then calculated using the DESeq package allowing for pooling of samples to compensate for lack of replicates. RNA Pol2 and LEO1 samples were compared independently. All plots were created using the NGSplot graphing toolkit [35]. Data were visualized at representative loci using UCSC genome browser. Data has been deposited in EMBL-EBI as SRP035339.

**Statistical analysis**

Data are represented as mean values and the error bars indicate ±SD. Groups were compared by two-tailed unpaired t-test. The significance is indicated as *** for P<0.001, ** for P<0.01 and * for P<0.05. For expression data multiple testing correction (q-values) were calculated using the Benjamini-Hochberg false discovery rate (FDR).

**Affinity purification and mass spectrometry**

Tandem affinity purification (TAP) for Merlin was performed from 10 x 15 cm dishes of HEK293T cells, transiently transfected with pcDNA3-TAP6 constructs. For CDC73, 20 x 15 cm dishes of HEK293T stably expressing TAP6-CDC73 (pLEX-MCS, Open Biosystems) and either Merlin or Ezrin (pLentiCMVBlunt, addgene 17486) were used. The TAP6-tag contains 3x streptactin, 2x histidine, SBP and FLAG tags. Cells were lysed in PBS-lysis buffer (LB) Clarified pooled lysates were incubated with Streptavidine Sepharose beads (GE Healthcare) and washed extensively with PBS containing 0.1% TX-100. Bound proteins were first eluted with 2 mM Biotin and then LDS sample buffer. Biotin eluates were TCA precipitated, separated on 4–12% NuPAGE gels (Life Technologies) and stained with SimplyBlue SafeStain (Life Technologies).

Gels were cut along the lanes in several pieces, and proteins were digested in-gel with trypsin as described previously [36] (donatello.ucsf.edu/ingel.html). The extracted digests were vacuum-evaporated and resuspended in 10 μl of 0.1% formic acid in water, except the slice containing the bait, that was resuspended in 30 μl. The digests were separated by nano-flow liquid chromatography using a 75 μm x 150 mm reverse phase C18 PepMap column (Dionex-LC-Packings, San Francisco, CA) at a flow rate of 300 nl/min in a NanoLC-1D Proteomics high-performance liquid chromatography system (Eksigent Technologies, Livermore, CA, USA) equipped with a FAMOS autosampler (Dionex-LC-Packings, San Francisco, CA).

Mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile. Following equilibration of the column in 5% solvent B, 5 μl of the digests were injected, then the organic content of the mobile phase was increased linearly to 40% over 60 min, and then to 50% in 1 min. The liquid chromatography eluate was coupled to a microion-spray source attached to a QSTAR Pulsar mass spectrometer (Applied Biosystems/MDS Sciex, South San Francisco, CA, USA). Peptides were analyzed in positive ion mode. MS spectra were acquired for 1 s in a m/z range between 310 and 1400. MS acquisitions were followed by 3 s collision-induced dissociation (CID) experiments in information-dependent acquisition mode. For each MS spectrum, the most intense multiple charged peaks over a threshold of 30
counts were selected for generation of CID mass spectra. The most common trypsin autolysis products (m/z = 523.280$^{+2}$, 421.750$^{+2}$, 737.700$^{+3}$) were excluded. The CID collision energy was automatically set according to mass to charge (m/z) ratio and charge state of the precursor ion. A dynamic exclusion window was applied which prevented the same m/z from being selected for 1 min after its acquisition. Typical performance characteristics were 10000 resolution with 30 ppm mass measurement accuracy in both MS and CID spectra.

A second 5 μl aliquot of the samples was injected using the same chromatographic setting into a hybrid linear ion trap-Fourier transform mass spectrometer (LTQ-FT, Thermo Scientific, San Jose, CA) equipped with a nanoelectrospray ion source. Spraying was from an uncoated 15 μm-inner diameter spraying needle (New Objective, Woburn, MA). Peptides were analyzed in positive ion mode and in information-dependent acquisition mode to automatically switch between MS and MS/MS acquisition. MS spectra were acquired in profile mode using the ICR analyzer in the m/z range between 310 and 1600. For each MS spectrum, the 5 most intense multiple charged ions over a threshold of 200 counts were selected to perform CID experiments. Product ions were analyzed on the linear ion trap in profile mode. CID collision energy was automatically set to 35%. A dynamic exclusion window of 1 Da was applied that prevented the same m/z from being selected for 60 s after its acquisition.

Peak lists from files acquired by both instruments were generated using Mascot Distiller version 2.1.0.0 (Matrix Science, Boston, MA). Parameters for MS processing were set as follow: peak half-width, 0.02; data points per Da, 100. Parameters for MS/MS data were set as follows: peak half-width, 0.02; data points per Da, 100. The peak list was searched against the human subset of the UniProtKB database as of December 16, 2008 (containing 167288 entries) using in-house ProteinProspector version 5.2.2 (a public version is available online). A minimal ProteinProspector protein score of 15, a peptide score of 15, a maximum expectation value of 0.1 and a minimal discriminant score threshold of 0.0 were used for initial identification criteria. Carbamidomethylation and acrylamide modification of cysteine; acetylation of the N-terminus of the protein and oxidation of methionine were allowed as variable modifications. Peptide tolerance in searches of QStar data was 100 ppm for precursors and 0.2 Da for product ions; for LTQ-FT data was 30 ppm for precursors and 0.6 Da for product ions, respectively. Peptides containing two miscleavages were allowed. The number of modification was limited to two per peptide. Carbamidomethylation and formation of acrylamide adducts of cysteine, N-acetylation of the N-terminus of the protein, oxidation of methionine, phosphorylation of serine, threonine or tyrosine, and acetylation of lysine were allowed as variable modifications.

Hits were considered significant when three or more peptide sequences matched a protein entry and the Prospector score was above the significant level. For identifications based on one or two peptide sequence with high scores, the MS/MS spectrum was reinterpreted manually by matching all the observed fragment ions to a theoretical fragmentation obtained using MS Product (Protein Prospector) [37] Number of unique peptides reported combines the results of the searches for both sets of data. Normalized spectral counts were calculated normalizing the total number of spectra acquired for each protein (combining data from both instruments) and normalizing by the length of each polypeptide.

**CDC73 interactome**

The final interactome list contained proteins that were identified with at least 2 unique peptides with the CDC73 bait but not an unrelated bait purified in parallel. Label-free quantification was estimated by spectral counts that were normalised to the CDC73 bait. A normalisation factor of 15% was calculated (Merlin-CDC73/Ezrin-CDC73 = 1.15) and used to adjust the spectral counts of the Ez pulldown. A Merlin/Ezrin fold change was calculated for the proteins
detected in both pulldowns. Proteins detected in one pulldown only with at least 3 peptide counts were defined as upregulated (absent in Ez) or downregulated (absent in NF2) to a higher degree than if detected in both pulldowns. The protein list was loaded into DAVID [38] for functional annotation analysis with Gene Ontology (GO) terms. Top ranked enriched functional clusters of GO terms were selected and used to fully annotate the protein interactome list within the QuickGO browser for Gene Ontology terms and annotations. The protein list was then loaded into the STRING database of functional protein association networks where textmining, experiments, and databases were used as active interaction sources to generate a network at medium confidence. The network was exported and loaded into Cytoscape 3.3.0 for integrating the network with attribute data (fold change regulation and functional terms) and visualizing these.

**siRNA Oligos:** NF2-1: ACCAUGGAGCGCCGAGAUGGAGUUCUA, NF2-2: AAUGGCCAAC GAAGCACUAGAU; CDC73-2: GCCCAAGAAGUGAAAGACCAACUAU; CDC73-3: CAGCAGAUCAUCUAGACUCAA; CHD1-1: CCGCAGAUCAGGCAGAUCUUUACAAA; DD1-1: GUGACAGCGCUUGACAUACUUGAAU; LE01: CCAGUUACCCUGAAGCCGUAU; PAFL: GCCCAAGUGCCAGUGCAACUAGAU; RTF1: GGUGUUGU GGAAACUGUCCAAAGU; SK1: ACUGCUUCAGAUGGCUCACAU; TAT-SF1: GAAGUGCUCAAGAACUGCAACUG; VPRBP: ACCGGUGUCAUGUGUUGUUAUU; FAT1: CCAACACACCCUGUGGUCAUGUU; FAT3: CCCAGAGUGGU GUAUCUCUAA; FAT4: CCAAGGAUGUGGUUCCUAACAU; Scramble: UUCUCCGAACGUGACUUU

**Primers for ChIP-qPCR**
ANKRD1-A: CGATGTGATCACCCACCAAG and GAGGGAGGAGCAAGCTTACC.  
ANKRD1-B: TTCCTTCTTGGAGATTTCAGA and GTCACAGGTGGGTGCTAGAAG.  
ANKRD1-Z: CCGGAGCAAGATGCATTA and CCAGCTCCAGGAATTCTCGAG.  
CSF3-A: GCATTGTCTTGGACACCAGT and GAGGCCTGGGAGGAAATTA.  
CSF3-B: GCTTGAGCCAACCTCATAGC and AGCTGCAGTGCTGCTGAGG.  
CSF3-Z: AGAGGCCCGAGGTCATTCC and GAAACTGGAGCCATCTTC.  
CST1-A: GCTGCCAAAGCCAGAAGATTAAAT and GAGGCCTGGGAGGAAAAT.  
CST1-B: GTACAGGCTGCCCATTCACTT and GCAGCGGAGGCTGCTGATAG.  
CST1-Z: CCAGGAGCTTTCCACCTTCTTG and CCTGGTCAGGCTGCTCT.  
CYR61-A: CCAACACGATTTCTGAGAT and GAGCCCGGTCTTTATACG.  
CYR61-B: AACAGGAGCTCAGCAAAAC and CTGCAGATCCCTTCAGAG.  
CYR61-Z: ATGATTTCAGCAGGACTC and TCCGGAGGCTGACTTAC.  
CTGF-A: AGTGTGCCCAGCTTTTTCAGC and CAATGAGCATTGAGGATCC.  
CTGF-B: CAGACAGCTGCAAGTACC and AAATGCTCGAGGAGTGGG.  
CTGF-Z: TCATAGATGTGAGGGGTGAC and CAAACCAATCCATCCACA.

**Primers for RT-qPCR**
ACTNB: TCCTTCTGAGGAG and AGGAGGACGATGCTTCTGTGCTTCTT.
AKR1C3: AGATTGCAGATGGCAGT GTG and TGAGTTTTCCAAGGCT GGTC.
AMOTL2: GACCACACTGCTGTCACTG and CTCCTAGATTTGGCTGCAGGT.
ANKRD1: CAATCCAGATGGT TGTGATGAG and GGGCTCCAGCTTCCA TTAAC.
C3: CAGTGAGAAGACTGTGCT GACC and GCCCCTTTTCTGACTT GAAC.
CPA4: TGAAGTCCAGGGGCTTGAG and TCTTGCCCTTCATTTGTGGT.
CST1: ACAAGGCCCAACAAAGATGAC and GGGCTGGGACTTGGTACATA.
CTGF: GCAGGCTAGAAGCGAGAC and GCAGCCAGAAAGCTCAAAC.
CYP1B1: AACGTACCGGGAATCTACAC and CCACGACTTACATCCAATTCT.
CYR61: CCAGTGTACAGCAGCCT GAA and ACTTGGGCCGGTATTTCTC.
DDIT4: CTTGACACAGGACGACAT and CATCAGGTTGGCCACACAAAT.
DKK1: AGCAACTTTGAGGGATTTTC and CCTGAGGACAGCTTTGTA.
EDN1: GCTCGTCCCCTGATCCAA and CTGTGTGCTTGTGGGAAAT.
F3: CCAAAACCGTCAATCAAGTC and CACTGTGCTTACATCTCC.
FGF1: CAGGTGAAAGGACAAACAG and GGGCTGGGACTTGGTACT.
GAPDH: TGGAAATCCCATCACCATC and TGGACTCCACGACGTACT.
HAS2: GCCTCATCTGTGAGATGTT and CACTGCTGAGGAA ATGAGATCC.
IL1B: GCTTTCCTGTGAGATGTT and CACTGCTGAGGAA ATGAGATCC.
ITG2A: AGAACCGAATGGGAGATGTG and CTGTGTGCTTGTGGGAAAT.
KYNU: GCGGATGATAAAGCCA AGAG and ACCCCACTGAACAGGATCA C
MMP1: ACAGCCTCAGGGCAGACTCTA and CTGTGCTTACATCTCC.
NDRG1: CATGGTCTGTGTTCACAGT and GGCAAAGTGCTGGGTGA T
NF2: AAGCAACCAGACGTTCAC and GGTCCTCCCTTCACCTTC.
NLRP10: TGGACAGCTCAGGCCTATT and TGCTTGCCCTTCATCTCT.
RAB27B: AGTCAATGAAAGCAGACTCTA and TCTGAGGACTTGGTACTT.
SERPINA3: GCTCAGAGACCCCTGAAG and GATGAAAACCTTGGCAGGT.
TCP11L2: AACAGAGGGCCTCTCCAGAA and ATAAGAGACGTCCACAGAAG.
TGFB2: ATAGACATGCGGCCCTTCTT and CTCCATTGCTGACATGTC.
partners such as the VPRBP/DCAF1 and DDB1, members of a Cullin 4 containing E3 ubiquitin ligase complex (CRL4\textsuperscript{VPRBP}) [12, 19, 39] and AMOTL1, a tight-junction associated protein [12, 19, 39]. We also identified here new proteins that co-purified specifically with Merlin (but not other control baits) such as: CDC73, PAF1, CTR9, LEO1, and SK18, all core components of the PAFC; CHD1, a chromatin remodeler implicated in elongation [40]; components of the U2 small ribonucleoproteins complex (U2 snRNP) of the spliceosome; TAT-SF1, an elongation factor linked to splicing [41] and PELP1, a protein that interacts with several transcriptional activators and chromatin-modifying proteins and has also been linked to splicing [42, 43] (Fig 1A and S1A Fig).

To validate the specificity of these interactions, we expressed Flag-tagged versions of Merlin, the three closely related ERM proteins, Ezrin, Radixin and Moesin, and the FERM-domain containing erythrocyte membrane protein band 4.1 (EPB41) in HEK293T cells. Immunoblotting of Flag-immunoprecipitates (IPs) showed that endogenous LEO1, PAF1, CDC73, CHD1,
PELP, TAT-SF1 and SF3A3 interact specifically with both Merlin isoforms 1 and 2 but not with the three ERM proteins or EPB41 (Fig 1B). RTF1, which has been shown to physically and functionally associate with the PAFC [44], was not identified by mass spectrometry but could be detected by immunoblotting in Flag-IPs. Similarly, the SPT16 subunit of the histone chaperone FACT associated with Merlin. Importantly, endogenous Merlin co-immunoprecipitated with the PAFC components as well as CHD1 and VPRBP in IOMM-Lee meningioma cells [45] (Fig 1C), confirming that these interactions take place at physiological levels of Merlin as well as in the absence of SV40 Large T antigen that is expressed in HEK293T cells [46].

Most of the novel Merlin interactors we identified are involved in transcription and this is consistent with the nuclear localization of a pool of Merlin [10, 16, 17, 20]. Indeed, in cell fractionation experiments endogenous Merlin can be readily detected in the nuclear fraction together with all the identified interactors (Fig 1D and S1D Fig) consistent with these interactions taking place in the nucleus.

In an effort to shed light on the nature of these Merlin interactions (e.g. direct vs indirect), we measured Merlin associations in Flag-Merlin IPs after knock-down with siRNAs of different interactors. Knockdown of TAT-SF1 or CHD1 had no effect on Merlin’s interaction with PAFC subunits (only CDC73 shown) and conversely, knockdown of PAFC subunits had no effect on Merlin’s interaction with TAT-SF1 or CHD1, suggesting the PAFC, TAT-SF1 and CHD1 bind independently to Merlin (Fig 1E). Knockdown of TAT-SF1 did inhibit the interaction with U2 snRNP complex components SF3A3 and SF3B1, consistent with Merlin binding the U2 snRNP complex indirectly via TAT-SF1, [41]. Knockdown of CDC73, PAF1 and SK18 subunits of the PAFC, but not CHD1, inhibits the Merlin-SPT16 interaction, suggesting the FACT complex associating indirectly with Merlin through the PAFC (Fig 1E). In contrast, knockdown of PAFC subunits did not have any effect on binding of RTF1 and similarly knockdown of RTF1 had no effect on the interaction with PAFC subunits, consistent with them having independent roles [47, 48]. Knockdown of VPRBP only inhibited the interaction of Merlin with DDB1, consistent with DDB1 binding indirectly through VPRBP [19, 39]. A model summarizing the data derived from these experiments is provided in Fig 1F.

Because of Merlin’s role in contact inhibition, the effects of cell density on Merlin’s interactions were studied. HEK293T, IOMM-Lee meningioma and HMLE non-transformed mammary epithelial cells http://www.ncbi.nlm.nih.gov/pubmed/11156605 [49] stably expressing Flag-Merlin were analysed for their ability to co-IP endogenous proteins in either confluent or very sparse cells, where a minimal number of cell-cell contacts are formed (S1D and S1E Fig). Cell density had no effect on the interactions with VPRBP, CHD1, TAT-SF1 and the SF3A/B complex (Fig 1G and S1C–S1E Fig). In clear contrast, the interaction with the PAFC and RTF1 was strongly reduced under confluent conditions (Fig 1G and S1E and S1F Fig). Conversely, Merlin displays a reduced interaction with AMOT and AMOTL1 under sparse conditions (Fig 1G and S1E and S1F Fig) in agreement with a previous report [12]. Thus, cell density can differentially modulate Merlin association with different binding partners, with Merlin’s interaction with the PAFC and AMOT family proteins being inversely regulated.

We note that the ability of the PAFC to interact with Merlin in sparse conditions correlates with a slower electrophoretic migration in SDS-PAGE of LEO1 and PAF1 subunits as well as CHD1 (Fig 1F and S1E and S1F Fig) that is consistent with phosphorylation. This suggests that signalling originating from cell-cell contacts controls post-translational modification of several Merlin interacting proteins in the nucleus, and at least in the case of the PAFC, this correlates with its ability to interact with Merlin.
CDC73 is required for growth inhibition by Merlin and inactivating mutations in both Merlin and CDC73 mutually disrupt their interaction

To map the region of Merlin mediating these novel interactors we expressed GST-fusion proteins of the N- and C-terminal halves of Merlin containing the FERM domain or α-helical and C-terminal domains respectively (Fig 2A). Merlin associates with the PAFC, CHD1 and VPRBP whereas AMOT and AMOTL1 bind to Merlin’s C-terminus. TAT-SF1 only associates with full length Merlin. GST-Merlin and -Radixin were transfected and purified from HEK293T cells and bound proteins detected by wb. (C) The PAFC, CHD1 and VPRBP bind to different regions of Merlin’s FERM domain. Recombinant GST-proteins were used in ‘fishing’ experiments from cell lysates and associated proteins detected by wb. (D) Mutations in Merlin selectively disrupt interactions. Flag-Merlin was immunoprecipitated from HEK293T cells and endogenous proteins detected by wb. (E) B41-domain Merlin mutants are defective for VPRBP binding under more stringent experimental conditions. As in E but cells were lysed and IPs washed in RIPA buffer containing 0.5% DOC, 0.1% SDS. (F) Inhibition of cell proliferation by Merlin correlates with its ability to interact with the PAFC. Clonogenic assays of SF Merlin-deficient SF1335 meningioma cells infected with retroviruses expressing either Ezrin, Merlin wt or Merlin mutants and stained with crystal violet.

https://doi.org/10.1371/journal.pone.0254697.g002
The FERM domain is composed of three structurally distinct modules (F1, F2 and F3) that together form a clover-shaped structure. In ‘fishing’ experiments with recombinant proteins, both wild type Merlin and the FERM domain pulled down the PAFC, CHD1 and VPRBP from cell lysates (Fig 2C). The tumour-derived L46R substitution that maps to the F1 lobe strongly disrupted the interaction with the PAFC and CHD1 but only had a partial effect on VPRBP. Similarly, a Merlin deletion mutant lacking the F1 and F2 subdomains of the FERM domain (ΔB41) was unable to interact with the PAFC and CHD1 but could still bind to VPRBP (Fig 2C). To further dissect the interactions, a panel of tumour-derived Merlin mutations distributed throughout the protein were tested for their ability to co-IP endogenous proteins. Mutations within F1 and F2 lobes of the FERM domain (L46R, L64P, ΔF118, A211D) or deletion of exons 2 and 3 within the F1 subdomain disrupt Merlin’s interaction with the PAFC but not VPRBP or AMOT (Fig 2D). The L234R substitution, which lies adjacent to the F2 in the F3 subdomain, does disrupt the interaction with VPRBP (as well as PAFC) (Fig 2D). L535P and Q583P in the C-term domain specifically disrupt interaction with AMOT consistent with its interaction with the C-terminus of Merlin [12].

Our findings on the ability of some FERM domain point mutants such as L46R to still interact with VPRBP (although in an impaired manner) are in contrast to those of Li et al. [19]. We reasoned that different experimental conditions could account for these discrepancies since more stringent lysis and washing conditions (RIPA buffer containing 0.1% SDS) were used in their assays. When similar experiments were performed using RIPA buffer the Merlin-VPRBP interaction can indeed now be observed to be disrupted by FERM domain mutations (Fig 2E) in agreement with Li et al. [19]. Taken together our data suggest that Merlin uses distinct regions of the FERM domain to interact with different proteins, with the F1 and F2 subdomains (B41 domain) mediating the interaction with the PAFC and CHD1 and the F3/FERM-C subdomain primarily mediating the interaction with VPRBP, although substitutions within the other FERM lobes may weaken the affinity for VPRBP and make it more prone to dissociation under certain experimental conditions.

We next assessed the ability of our panel of tumour-derived Merlin mutants to inhibit proliferation when expressed in Merlin-deficient cells SF1335 meningioma cells, where both Merlin isoforms 1 and 2 potently inhibit proliferation in clonogenic assays (Fig 2F). Surprisingly, many of the tumour-identified mutants were still able to inhibit proliferation as efficiently as wild type Merlin (Fig 2F) suggesting these mutations may impair function via decreased protein stability rather than functional activity [50] a property that could be overcome by overexpression in our experimental system. Strikingly, only the mutations within the FERM domain (L46R, ΔF118, A211D, L234R) that disrupt the Merlin-PAFC interaction (Fig 2D), were unable to inhibit proliferation of SF1335 cells (Fig 2F). Splice site mutations are frequently found in NF2 and can lead to deletion of exons 2 and/or 3 [51]. A Merlin deletion mutant lacking amino acids coding for exons 2 and 3 was also defective in its ability to inhibit tumour cell proliferation (Fig 2F). Therefore, there is a good correlation between the ability of Merlin to inhibit proliferation and its interaction with the PAFC.

To study the contribution of the PAFC to growth inhibition by Merlin, Merlin-deficient SF1335 meningioma cells were infected with retroviruses expressing YFP-Ezrin or -Merlin and the cell cycle profile of YFP positive cells was analysed using flow cytometry. Merlin expression led to a pronounced G1 arrest two days after infection whereas expression of Ezrin had no effect (Fig 3A). Knock-down of CDC73 with two different siRNA oligos significantly inhibited Merlin-induced G1 arrest (Fig 3B–3D). This data suggests that CDC73 is required for Merlin’s tumour suppressor function.

We next considered whether tumour derived inactivating mutations in CDC73 might exhibit deficiencies in its interaction with Merlin in co-transfection experiments. In contrast
with the CDC73 227x truncation mutants that is unable to interact with Merlin or PAFC sub-units, CDC73 413x is unable to bind to Merlin (Fig 3F) but still interacts with other PAFC sub-units as previously reported [52]. Similarly, the CDC73 L95P missense substitution [53, 54] had no effect on its interaction with other PAFC subunits but disrupted the interaction with Merlin (Fig 3F). Thus, inactivating mutations in CDC73 disrupt the interaction with Merlin without necessarily influencing the interaction with other PAFC subunits, suggesting that the ability to interact with Merlin is important for CDC73 tumour suppressor function.

### CDC73 is a potential substrate of CRL4\(^{\text{VPRBP}}\)

Merlin interaction with VPRBP E3 ligase complex (CRL4\(^{\text{VPRBP}}\)) in the nucleus is an important mediator of Merlin effects on gene expression [19]. Because VPBRB and PAFC interact with...
Merlin in a non-mutually exclusive manner, primarily through different FERM subdomains, they would be expected to be in close proximity within a complex with Merlin. We thus tested whether subunits of the PAFC could be targets of ubiquitination by CRL4\textsuperscript{VPRBP}, as has been described for LATS kinases, themselves Merlin interactors [7, 8].

To examine whether CDC73 is ubiquitylated in vivo, HEK293T cells were transfected with HA-ubiquitin, indicated Flag-proteins and either empty vector or VPRBP. Flag IPs were immunoblotted as indicated. The asterisk points to a band corresponding to Flag-AMOTb bait that crossreacts with the HA-antibody. (B) 293T cells were transfected as above with but using TAP6-CDC73 (containing a tandem His tag and Flag tag) and lysed and purified under denaturing condition. Talon beads pull-downs were immunoblotted as indicated. Asterisk points to a band corresponding to the TAP6-CDC73 bait that cross-reacts with the HA antibody on lycor. (C) VPRBP/DCAF1 but not other DCAFs stimulate CDC73 ubiquitination. As in A but comparing Myc-VPRPB to other Myc-DCAFs. (D) Merlin partially inhibits VPRBP stimulated ubiquitylation of CDC73. Flag-CDC73 was transfected with HA-UB and either Merlin or Ezrin as control as in A. Ubiquitin associated with Flag-IPs was detected by wb with an HA antibody. (E) Endogenous CDC73 co-IPs with VPRBP in multiple cell lines. WB: Western blot, IP: Immunoprecipitation, PD: Pull down.

https://doi.org/10.1371/journal.pone.0254697.g004
either Merlin or Ezrin. Merlin expression inhibited, albeit modestly, VPRBP stimulated ubiquitination of CDC73 (Fig 4D) consistent with Merlin’s inhibition of CRL4VPRBP activity [19].

VPRBP stimulated ubiquitination of CDC73 correlates with their ability to form a complex in vivo as endogenous CDC73 and VPRBP co-IP in multiple cell lines (Fig 4E). Taken together, these observations suggest that CDC73 is a target of CRL4VPRBP mediated ubiquitination and thus Merlin regulation and/or co-recruitment of CRL4VPRBP may provide a molecular mechanism of PAFC regulation by Merlin.

A gene expression program associated with hypersensitivity to growth inhibition by Merlin

In order to study gene regulation by Merlin, we first characterized expression of Merlin and its interactors in cell lines derived from multiple tumour types. All Merlin interactors tested were found to be ubiquitously expressed (Fig 5A). On the other hand, in addition to mesotheliomas and meningiomas, Merlin expression was absent or aberrant in cell lines derived from diverse tumour types (Fig 5A and S2A and S2B Fig). Whereas Merlin expression was not detectable in some cell lines, a significant proportion of them (5 out of 11) displayed a faint band of a shorter product in whole cell lysates (Fig 5A) or by IP using two different Merlin antibodies (S2B Fig). This is consistent with splicing mutations as a mechanism of Merlin inactivation [55].

When Merlin was expressed ectopically, cell lines with wild type Merlin were insensitive to Merlin expression (with only one exception (1 of 11)) and grew at the same rate as Ezrin-expressing or empty vector controls (Fig 5B). In contrast, proliferation of all Merlin-deficient cells (11 of 11 lines) was strongly inhibited by Merlin re-expression (Fig 5B). This is consistent with the concept of ‘oncogene addiction/tumour suppressor gene hypersensitivity’ [56] and suggests that in tumours with NF2 mutations, absence of Merlin expression is required for proliferation, regardless of tumour type and/or of additional somatic mutations (S2A Fig).

To study how Merlin selectively induced growth arrest in Merlin-deficient cells and shed light on Merlin-regulated genes, we analysed by microarray global gene expression after expressing either Merlin wt or an inactive L46R mutant that is unable to interact with the PAFC (Fig 2D) in a set of four cell line pairs derived from different tumour types (S2C Fig). Whereas in Merlin-deficient cells, re-expression of wt Merlin causes large changes in gene expression, the response in Merlin wt cells is marginal (Fig 5C), with only 5 significant changes (fold change >1.5, q<0.05) (S2D Fig and S1 Table). In contrast, there was a consistent cross tissue signature of 247 gene changes (85 down, 162 up, fold change >1.5,q<0.05) shared across the 4 different Merlin-deficient cell lines (Fig 5D and S2 Table) hereby referred to as the Merlin re-expression/hypersensitivity signature. Therefore, the ability of Merlin to suppress proliferation correlates with its ability to regulate a characteristic gene expression program.

Validation of selected Merlin-regulated genes by quantitative RT-PCR is shown in S3 Fig.

Ingenuity pathway analysis revealed the Merlin gene expression signature is highly enriched for genes encoding plasma membrane and extracellular proteins (Fig 5E) suggesting a role for Merlin in cellular communication with the microenvironment. Knowledge based pathway analysis by gene set enrichment analysis (GSEA) [57] revealed Merlin re-expression caused downregulation of genes involved in cell cycle progression and DNA replication (Fig 5E and S4 Fig) consistent with the growth inhibition observed in Merlin-deficient cells. On the other hand, upregulated pathways suggest a transcriptional role for Merlin in inflammation and innate immunity (Fig 5E and S4 Fig). Consistent with a functional link between Merlin and Hippo signaling a conserved YAP transcriptional signature is strongly downregulated by Merlin expression (S4C Fig). Coordinated up/down regulation of several transcriptional signatures
also suggests possible functional relationships between Merlin and other transcriptional pathways (S4C Fig).

**Merlin is involved in the transcriptional response to high cell density**

To further define genes regulated by Merlin and their relationship to contact inhibition, microarray experiments were performed after Merlin depletion in HMLE cells at both high and low cell densities. HMLE cells where Merlin expression was inhibited show far fewer significant changes than control cells in response to high cell density (S5A Fig): In control
cells 801 (449 up, 352 down) genes were significantly regulated (fold change >1.5, p<0.05) compared to only 60 (48 up, 12 down) in Merlin knock-down cells (S5B Fig and S3 and S4 Tables). Validation by qPCR of selected genes regulated by high cell density is shown in S6C Fig.

Comparison of a high cell density gene signature with the Merlin re-expression/hypersensitivity signature shows a significant positive overlap (chi-square, p < 0.001, Figure SED). Out of the 251 genes regulated by Merlin re-expression in tumour derived cell lines over 20% (52 genes) are regulated by high cell density in the same direction in HMLE cells (S5 Table). This is consistent with growth suppression by Merlin being mediated at least partly by some of the same transcriptional changes that mediate contact dependent inhibition of proliferation. Merlin knockdown caused substantially more transcriptional changes in dense cells than in sparse cells consistent with its role in contact inhibition. However, Merlin inhibition in sparse cells still induced substantial changes suggesting Merlin has a wider role in transcription beyond regulation by high cell density (S5E Fig, S6 and S7 Tables).

To verify the relevance of these gene signatures, we used the Oncomine concepts platform (https://www.oncomine.org). Genes that are negatively regulated by Merlin in our signatures overlap significantly with overexpressed genes in NF2-deficient cells from a multi cancer cell line study [58] (S5G Fig) validating the integrity of our signatures. We reasoned that regulated genes moving in the opposite direction in the re-expression/hypersensitivity and knockdown signatures would meet the most stringent criteria for Merlin target genes and are hereby defined as the Merlin core signature (S5H Fig and S12 Table). Strikingly, a majority (~ 63%) of the genes within this signature code for cell surface-bound and secreted proteins (S5H Fig) highlighting again a key role for Merlin’s transcriptional response in cell communication with the microenvironment.

Merlin regulates PAFC association with the chromatin of a subset of genes

Given Merlin’s physical interaction with the PAFC, we next set out to study whether Merlin can regulate the association of PAFC with the chromatin of selected genes. In an initial study using EGF-stimulated association with FOS gene by chromatin immunoprecipitation followed by PCR (ChIP-PCR) [59] we found that an antibody against the LEO1 subunit of the PAFC gave higher signal-to-noise ratios than the antibodies against CDC73, PAF1 or CTR9 subunits tested. Similarly, among the Merlin-deficient cells tested, MDA-MB-231 gave the highest signal-to-noise ratios. Therefore a LEO1 antibody was used, in parallel with a RNA pol II antibody, for ChIP-seq in MDA-MB-231 cells infected with lentiviruses expressing either Merlin wt or the PAFC interaction-defective L46R Merlin mutant.

The vast majority of RNA Pol II bound genes are also bound by LEO1 (Fig 6A), in line with a general role of the PAFC in gene expression [25]. When the binding profiles for representative genes are compared, RNA Pol II is found predominantly at the transcription start site (TSS), whereas LEO1 peaks downstream of the TSS and follows RNA Pol II throughout the coding region (Fig 6B), consistent with a role of the PAFC in pause release and elongation [25].

Expression of wt Merlin regulates the association of LEO1 and RNA Pol II with only a relatively small subset of genes (129 on LEO ChiP, 92 on Pol II ChiP, fold change >+/- 1.5) (Fig 6C, S9 and S10 Tables). With the cut-offs used, 27 genes were identified where Merlin regulates both RNA Pol II and LEO1 binding (Fig 6D). The majority of these (20 of 27) were also found transcriptionally regulated by Merlin in the microarray experiment in MDA-MB-231 cells. Plots of the short read coverage for selected Merlin-regulated genes are shown in Fig 6E and validation by ChIP-qPCR in Fig 6G. Taken together these results suggest that Merlin can
regulate the ability of the PAFC to associate with selected genes and this correlates with the concomitant regulation of their transcript levels.

Proteomic analysis of the CDC73 interactome highlights a role for FAT cadherins in Merlin’s interaction with the PAFC

In an effort to better understand at the molecular level how Merlin regulates PAFC function we used affinity proteomics to investigate the PAFC interactome and its regulation by Merlin. TAP6-tagged PAF1, LEO1 and CDC73 subunits of the PAFC were stably expressed in Merlin wild-type HT1080 and Merlin-deficient MDA-MB-231 cells. Affinity purification followed by mass spectrometry (AP-MS) identified in all cases the other subunits of the PAFC as the main co-purifying proteins. Other proteins were also co-purified, mostly with roles in RNA processing and transcription although surprisingly there was also a cluster of proteins associated with cell-cell contacts (S6A Fig and S11 Table). Many co-purified with all 3 subunits consistent with...
co-purification of the whole PAFC complex, but subunit-specific as well as cell line-specific interactors were also found (e.g. FAT1 and TP53 in Merlin-deficient MDA-MB-231 cells and FTSJ3 and ZZEF1 in Merlin wt HT1080 cells (S6B and S6C Fig, S11 Table).

To further investigate Merlin regulation of the PAFC interactome while avoiding variability associated to inter-cell line comparisons, we performed AP-MS of the TAP6-CDC73 subunit in HEK293T cells co-expressing either Merlin or Ezrin as a control. Most purifying proteins identified were nuclear proteins involved in transcription. However, there was again a significant fraction of proteins associated with cell junctions and cell adhesion (Fig 7A and S12 Table) suggesting a direct link between cell-cell contacts and CDC73 function. Using peptide counts as a semi-quantitative measurement, Merlin expression decreased association with several proteins, mainly involved in cell adhesion, whereas it increased association of other proteins mainly involved in transcription and chromatin remodeling, including subunits of the Nucleosome Remodeling Deacetylase (NuRD) complex (Fig 7B and S12 Table). Therefore, Merlin can both positively and negatively regulate CDC73 association with different sets of proteins.

A comprehensive validation of all these candidate direct or indirect interactions is beyond the scope of this study. However, we were particularly intrigued by the link between CDC73 and cell-cell adhesion and in particular with its association with FAT cadherins. FAT1, which like CDC73 functions as a tumour suppressor [60], was found associated with CDC73 in independent AP-MS experiments in 293T and MDA-MB-231 cells (S11 and S12 Tables) and we thus focused on this interaction for this study. Endogenous FAT1 can be readily detected associating with Flag-CDC73 in co-IP experiments and this interaction is not affected by Merlin expression (Fig 7C). This, together with the observation that FAT1 also copurified with CDC73 in Merlin-deficient MDA-MB-231 cells (S11 Table), suggests CDC73 and FAT1 interact independently of Merlin.

We next investigated whether FAT proteins could regulate the Merlin-PAFC interaction. We used siRNAs to knock-down all FAT isoforms expressed in 293T cells (FAT1, FAT3 and FAT4 as determined by RT-PCR) and assessed Flag-Merlin interactions with endogenous proteins in both dense and sparse cells as before. Strikingly, knock-down of FAT cadherins strongly inhibits Merlin interaction with PAF1, LEO1 and CDC73 PAFC subunits under sparse conditions whereas there was no effect on other Merlin interactors such as VPRBP, AMOT, CHD1 or RTF1. Thus, FAT cadherins are required for Merlin’s association with the PAFC.

**Discussion**

We show that Merlin interacts with a set of nuclear proteins involved in gene expression at post-initiation steps including the PAFC, RTF1, the CHD1 chromatin remodeller and the TAT-SF1 elongation/splicing factor. Interactions between the PAFC, RTF1, CHD1 and TAT-SF1 have been previously reported and suggest a shared role in elongation and splicing [59, 61].

Several of these Merlin interactors are themselves deregulated in cancer. The CDC73 subunit of the PAFC functions as a tumour suppressor [30] and we show CDC73 is required for growth inhibition by Merlin. Furthermore, tumour derived inactivating CDC73 mutations disrupt its interaction with Merlin whereas conversely, inactivating Merlin mutations disrupt the interactions with the PAFC. We also show that the interaction between Merlin and the PAFC is regulated by FAT cadherins, which are themselves mutated across various cancer types [60, 62]. Additionally, CHD1 is mutated in prostate cancer [63–65] and through TAT-SF1, Merlin interacts with the U2 snRNP complex of the spliceosome, whose
Fig 7. FAT cadherins interact with CDC73 and are necessary for Merlin interaction with PAFC. (A) Gene Ontology term enrichment of the CDC73 interactome in 293T cells. TAP6-CDC73 was affinity purified from 293T cells co-expressing either Merlin or Ezrin. Co-purifying proteins were subjected to functional annotation analysis with GO biological process, cellular component and molecular function terms using DAVID [38]. Top 5 results shown. Terms correspond to GO:0010332, GO:0005911, GO:0016569, GO:0016593 and GO:0016581. (B) Bioinformatics analysis of the CDC73 interactome and its regulation by Merlin. Proteins from the STRING functional network were annotated with log2 fold change regulation in Merlin- vs Ezrin-expressing cells (red, upregulated; blue, downregulated in cells over-expressing Merlin; white, unchanged). The shape of protein nodes represents the functional annotations (ellipse: transcription; diamond: cell contacts; hexagon: annotated with both transcription and cell contacts; rectangle: not annotated with these terms). Proteins highlighted with a background surface were annotated with functional terms and cluster together in the network. See also S12 Table and supplementary methods. (C) Validation of some interactions identified by CDC73 AP-MS. Flag-CDC73 or Flag-GFP were expressed in 293T cells with either empty vector or Merlin and Flag-IPs probed with the indicated antibodies. (D) FAT cadherins are required for Merlin interaction with PAFC. 293T cells were transfected with scramble or siRNAs against FAT1, FAT3 and FAT4 and 24 hours later transfected with either Flag-Ezrin or Merlin. Flag immunoprecipitates from dense or sparse cells were probed as indicated.

https://doi.org/10.1371/journal.pone.0254697.g007
components are also frequently mutated in several cancer types [66]. Taken together these findings suggest a function for nuclear Merlin as part of a tumour suppressor network that helps regulate expression of target genes at the level of elongation, chromatin remodelling and/or RNA processing.

Growth inhibition by Merlin is associated with its ability to regulate a cross-tissue gene expression program that is also regulated by cell density. Merlin interacts with $\alpha$-catenin and Angiomotin junctional proteins and thus is well poised to respond to signals originating from cell-cell contacts. Cell density is known to regulate Merlin phosphorylation and activity [10] and we show that subunits of the PAFC as well as CHD1 are also likely post-translationally modified in a cell density dependent manner. Moreover, Merlin’s ability to interact with the PAFC is regulated by FAT cadherins and correlates with the ability of FATs to associate with the CDC73 subunit of the PAFC. Taken together, these results are consistent with a model whereby multiple signals originating from cell-cell contacts converge at the level of Merlin-PAFC interaction to mediate a gene expression program associated with contact inhibition of proliferation (S7 Fig).

Although transmembrane proteins with a large extracellular domain, FATs are regulated at the level of proteolytic processing by mechanisms similar to Notch and nuclear localization of FAT1 cytoplasmic tail and association with transcription regulators has been reported [67–71]. Interestingly, CDC73/Parafibromin has been reported to interact with the Notch intracellular domain (as well as $\beta$-catenin and Gli1) [72]. Conversely although CDC73 is predominantly nuclear, it has also been detected in the cytoplasm in some contexts [26, 73]. Future studies should shed further light on the nature and location of the interaction between the CDC73 and FAT tumour suppressor proteins. Regardless, their association with renal defects may provide an independent genetic link: in addition to cancer, FAT1 mutations are linked to glomerulotubular nephropathy and fat1 knockdown in zebrafish causes pronephric cysts [74, 75] whereas CDC73 mutations in HPT-JT syndrome are associated with renal lesions in 20% of cases, most commonly cysts [76].

Elongation and RNA processing control play a crucial role in regulated gene expression and provides an additional regulatory node in the transcription cycle to exert combinatorial control of transcription levels [22, 23]. In contrast to initiation, where target gene specificity can be provided by sequence specific transcription factors, far less is known about how elongation and RNA processing can be differentially regulated, with likely multiple mechanisms involved for individual genes or network of genes [22, 23].

The PAFC travels with RNA Pol II on most actively transcribed genes but Merlin regulates PAFC association with only a subset of genes. We propose that Merlin may function as a cofactor that modulates the activity of proteins involved in elongation and RNA processing towards a subset of genes regulated by cell adhesion. The molecular mechanisms involved remain to be determined. We have been unable to detect direct association of Merlin with chromatin by Chip-qPCR although technical/antibody issues cannot be excluded. On the other hand, CRL4$^\text{VPRBP}$-mediated ubiquitination is likely to play a role. Merlin independently interacts with both CRL4$^\text{VPRBP}$ and PAFC and is thus expected to bring them into the same macromolecular complex and we show that the CDC73 subunit of the PAFC is a likely target of CRL4$^\text{VPRBP}$-mediated ubiquitination. How this modification is regulated in vivo and how it affects PAFC function remains to be determined. It is worth noting that VPRBP was originally identified as the HIV VPR interacting protein and that many of the Merlin interactors identified in our study, including TAT-SF1, PAFC and CHD1, are used by HIV during its transcription cycle [77–79]. Although the role of VPR in the HIV cycle is still unclear, it is tempting to speculate that it may function in a manner equivalent to Merlin to target VPRBP to regulate PAFC-mediated transcription of viral target genes.
The gene expression data of this study is consistent with the known role of Merlin as an upstream regulator of the Hippo pathway [3, 9] as many of the genes in our Merlin signatures are known YAP target genes. However, our study also suggests that Merlin may provide an additional layer of regulatory control in the transcription cycle of some genes (S7 Fig). According to our proposed model, Merlin at the membrane may primarily regulate LATS phosphorylation of YAP/TAZ to promote TEAD-dependent Pol II recruitment and transcription initiation. In addition, a pool of nuclear Merlin, through its interaction with the PAFC (as well as CHD1, RTF1, TAT-SF1 and others) may modulate post-initiation steps such as pause release, elongation rate and/or RNA processing in a subset of target genes (S7 Fig).

Understanding these multiple regulatory nodes, how the function of nuclear Merlin is intertwined with its membrane function and how it helps coordinate the different steps of the transcription cycle of selected genes through its interaction with a network of nuclear tumour suppressor proteins will be important to design new therapeutic strategies for NF2 tumours as well as the many human cancers where this pathway is deregulated.

Supporting information

S1 Fig. Merlin interacts with the PAFC in a cell density dependent manner. (A) Proteins identified by mass spectrometry after 2 independent Merlin affinity purifications from HEK293T. Some peptides for no DDB1 were also found in the SHOC2 control bait used. (B) Merlin resides primarily in the nuclear fraction. IOMM-Lee cells expressing various shRNAs were fractionated into a cytoplasmic/membrane, nuclear and nuclear insoluble fractions and proteins detected by Western blot. The shRNA knockdown of Merlin and Vprbp serve as specificity control for the immunoblot. BRAF/CRAF are used as examples of cytosolic proteins whereas HRAS and EGFR are examples of membrane proteins. Some EGFR can also be detected in the nucleus consistent with previous observations (73). Histone H2B is a marker for nuclear insoluble fraction. (C) Merlin’s interaction with the PAFC is inhibited in confluent cells. Flag IPs from dense or sparse IOMM-Lee cells stably expressing Flag-Ezrin or Merlin were probed with the indicated antibodies. (D) Representative images of cell densities of IOMM-Lee cells at time of experiment in C. (E) Representative images of cell densities in HMLE cells in experiment in Fig 1G.

S2 Fig. Merlin regulates gene expression in Merlin deficient cells. (A) Summary of proliferation studies for all tested cell lines in Fig 5. Known NF2 mutations as well as other somatic mutations are listed. (1) COSMIC database, (2) (74), (3) M. Giovannini personal communication, (4) see S2B. (B) Characterization of Merlin expression by IP-wb. Merlin was IPed using antibodies directed against the N-terminus (A-19) and the C-terminus (E-2) and detected by wb using an anti-C-terminus antibody (Bethyl). Cal62, 8505C and ACHN show no Merlin protein expression, whereas CAKI-1, SF1335, SN12C, CH-157-MN, KT21MG1 express shorter protein products consistent with splice site mutations. (C) Experimental design of gene expression microarray experiment in tumour cell lines. Merlin deficient and Merlin wild type cell lines from 4 different tissue types were infected with lentiviruses expressing either wild type or L46R Merlin, RNA was isolated 48 hrs later and analysed using GeneChip Human Gene 2.0 ST Arrays (Affymetrix). (D) Merlin expression regulates gene expression in Merlin deficient but not Merlin wild type cells. Number of significantly regulated genes (q ≤ 0.05, fold change > 1.5) identified by microarray.
S3 Fig. Validation of microarray results shown in Fig 5 by RT-qPCR. cDNA from cells as in S2C was analysed by qPCR. Data is represented as gene expression relative to actin (ACTB) and normalized relative to Merlin L46R mutant. Error bars indicate SD from three independent experiments. Cal62 were not used in the array experiment, however data from one experiment is shown. Genes upregulated by Merlin expression are shown in red, downregulated in blue.

(PPTX)

S4 Fig. Gene set enrichment analysis of microarray data. (A, B) Gene Set Enrichment Analysis (GSEA) of Merlin re-expression microarray results compared by KEGG (A) or GO biological pathways (B). Top 5–8 up- and down-regulated gene set pathways shown. (C) Selected transcriptional signatures from Oncogenic Signatures database associated with Merlin hypersensitivity by GSEA. * note that YAP conserved signature only contains genes upregulated by YAP expression. NES, normalized enrichment score.

(PPTX)

S5 Fig. Merlin is involved in the transcriptional response to high cell density. (A) Gene expression changes in dense (D) and sparse (S) HMLE cells 3 days after transfection with scramble (Ctrl) or NF2 siRNAs were analyzed by microarray. siControl cells show greater dispersion of limma t-values compared to the theoretical null distribution (black line). (B) As in A but showing number of significantly regulated genes (p ≤ 0.05, fold-change >1.5). (C) Validation by RT-qPCR of representative genes regulated by cell density in HMLE cells. Fold change in dense compared to sparse cells. Error bars indicate SD from n = 3. (D) Overlap between the Merlin re-expression and high cell density signatures. The majority of genes (85%, 52 of 61) are regulated in the same direction (= =), while 9 are regulated in the opposite manner (! =). (E) Merlin knockdown has a greater effect on gene expression in dense cells. Number of significantly regulated genes (q ≤ 0.05, fold change >1.5) is shown. (F) Validation by RT-qPCR of representative genes regulated by Merlin knockdown in dense HMLE cells with two independent siRNAs. Gene expression relative to GAPDH and fold change normalized to siCtrl. Error bars indicate SD from n = 3. (G) Merlin and high cell density signatures detect NF2 mutational status in the Garnett et al multi-cancer cell line study using the Oncomine database. Significance and overlap shown. (H) Merlin core gene signature is enriched in extracellular and plasma membrane proteins. Merlin core signature is defined as genes regulated in the opposite direction upon Merlin re-expression in 4 tumour cell lines and knockdown in dense HMLE cells. Red indicates positively regulated by Merlin (downregulated by knockdown and upregulated by re-expression), blue negatively regulated by Merlin (upregulated by knockdown and downregulated by re-expression). Protein location based on Gene ontology.

(PPTX)

S6 Fig. Proteomic analysis of PAF1, CDC73 and LEO1 subunits of PAFC. (A). Gene Ontology term enrichment of proteins co-purifying with PAFC subunits. TAP6-CDC73, PAF1 and LEO1 were expressed and affinity purified from either HT1080 (Merlin wild type) or MDA-MB-231 (Merlin deficient) cells. Co-purifying proteins identified by mass spectrometry were subjected to functional annotation analysis with GO biological process, cellular component and molecular function terms using DAVID (72). Terms correspond to GO:000368, GO:0098609, GO:0016593, GO:0006397 and GO:0000398. (B). Venn diagram showing overlap of proteins identified in HT1080 and MDA-MB-231. See S11 Table for full lists. (C). Venn diagram of proteins identified by AP-MS with each bait (CDC73, LEO1 and PAF1) in either HT1080 or MDA-MB-231 cells.

(PPTX)
S7 Fig. Model of Merlin’s dual role within the Hippo pathway to coordinate different steps in the transcription cycle of genes involved in contact inhibition. At the membrane, Merlin associates with cell-cell contact associated proteins such as a-catenin at adherens junctions and AMOT proteins at tight junctions whereas FAT cadherins may associate with the CDC73 subunit of the PAF complex at distinct adherens junctions. Merlin at the membrane primarily functions to regulate LATS-dependent phosphorylation and inactivation of YAP/TAZ. Upon Merlin inactivation (e.g. upon loss of cell-cell contacts), YAP/TAZ translocates to the nucleus to mediate TEAD dependent recruitment of Pol II and transcription initiation. In the nucleus, Merlin interacts with the CRL4\(^{VPRBP}\) E3 ubiquitin ligase (10) and with proteins involved in transcription elongation and RNA processing including the PAFC, CHD1, RTF1 and TAT-SF1 (this study). Through these interactions, Merlin regulates post-initiation events such as pause release, elongation rate and/or RNA processing in at least a subset of target genes. Merlin could use CRL4\(^{VPRBP}\) mediated ubiquitination of some associated proteins (such as CDC73 and/or other CRL4\(^{VPRBP}\) substrates) to regulate their properties and/or function within this macromolecular complex. Nuclear localization of FAT1 cytoplasmic tail and association with transcription regulators has been reported [59, 63] and the CDC73 interaction with FAT could also take place in the nucleus. AMOT also has dual membrane/cytoplasm and nuclear roles and is required for YAP transcriptional activity of some target genes [75, 76]. ZO-2, another tight-junction associated protein also interacts with YAP in the nucleus [77]. It is therefore possible that separate membrane/cytoplasm and nuclear functions of several of its components is a common feature of the Hippo pathway that allows for independent layers of regulatory control. Note that reported additional interactions of FAT with Hippo pathway components are not shown [76, 78] but also suggest multiple layers of regulation of the Hippo pathway by FAT proteins. Merlin may also cooperate/antagonize with transcription factors other than YAP/TAZ (not shown). AJ: adherens junctions, TJ: tight junctions.

(PPTX)

S1 Table. Genes regulated by Merlin expression in Merlin wild type cells.

(XLSX)

S2 Table. Genes regulated by Merlin expression in NF2 mutant cells.

(XLSX)

S3 Table. Genes regulated by high cell density in control siRNA HMLE cells.

(XLSX)

S4 Table. Genes regulated by high cell density in siNF2 HMLE cells.

(XLSX)

S5 Table. Genes regulated in the same direction by Merlin re-expression in 4 NF2 mutant cell lines and high cell density in HMLE cells.

(XLSX)

S6 Table. Genes regulated by NF2 knockdown in dense HMLE cells.

(XLSX)

S7 Table. Genes regulated by NF2 knockdown in sparse HMLE cells.

(XLSX)

S8 Table. Merlin core gene signature.

(XLSX)
S9 Table. Genes where Pol II association is regulated by wild type vs L46R Merlin expression in MDA-MB-231 by ChIP-seq.
(XLSX)

S10 Table. Genes where LEO1 association is regulated by wild type vs L46R Merlin expression in MDA-MB-231 by ChIP-seq.
(XLSX)

S11 Table. Proteins identified by mass spectrometry with TAP6-CDC73, -PAF1 or–LEO1 in HT1080 or MDA-MB-231 cells.
(XLSX)

S12 Table. Proteins identified by mass spectrometry after affinity purification of TAP6-CDC73 in HEK293T cells co-expressing either Ezrin or Merlin.
(XLSX)

Acknowledgments
We thank Arnold Pizzey for help with the FACS analysis; Anita Lal, David Gillespie, Julian Downward and Marco Giovannini for cell lines; Richard Jenner for help with ChIP assays, Nic Tapon, Richard Jenner, Paolo Salomoni, Benoit Bilanges and Daniel Hochhauser for critically reading the manuscript.

Author Contributions
Conceptualization: Anne E. Roehrig, Kristina Klupsch, Pablo Rodriguez-Viciana.
Data curation: Anne E. Roehrig, Kristina Klupsch.
Formal analysis: Kristina Klupsch, Warren Emmett.
Funding acquisition: Alma L. Burlingame.
Investigation: Anne E. Roehrig, Kristina Klupsch, Juan A. Oses-Prieto, Selim Chaib, Stephen Henderson, Lucy C. Young, Silvia Surinova, Andreas Bles, Anett Pfeiffer, Maha Tijani, Fabian Brunk, Nicole Hartig, Marta Muñoz-Alegre, Alexander Hergovich, Barbara H. Jennings, Alma L. Burlingame, Pablo Rodriguez-Viciana.
Supervision: Pablo Rodriguez-Viciana.
Writing – original draft: Anne E. Roehrig, Kristina Klupsch, Pablo Rodriguez-Viciana.

References
1. Hanahan D. and Weinberg R. A., “Hallmarks of cancer: the next generation,” (in eng), Cell, vol. 144, no. 5, pp. 646–74, Mar 4 2011, https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230
2. McClatchey A. I. and Yap A. S., “Contact inhibition (of proliferation) redux,” (in eng), Curr Opin Cell Biol, vol. 24, no. 5, pp. 685–94, Oct 2012, https://doi.org/10.1016/j.cceb.2012.06.009 PMID: 22835462
3. Cooper J. and Giancotti F. G., “Molecular insights into NF2/Merlin tumor suppressor function,” (in Eng), FEBS Lett, Review vol. 588, no. 16, pp. 2743–52, Aug 19 2014, https://doi.org/10.1016/j.febslet.2014.04.001 PMID: 24726726
4. Dalgliesh G. L. et al., “Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes,” (in eng), Nature, vol. 463, no. 7279, pp. 360–3, Jan 21 2010, https://doi.org/10.1038/ nature08672 PMID: 20054297
5. Forbes S. A. et al., “COSMIC: exploring the world’s knowledge of somatic mutations in human cancer,” (in eng), Nucleic Acids Res, Research Support, Non-U.S. Gov’t vol. 43, no. Database issue, pp. D805–11, Jan 2015, https://doi.org/10.1093/nar/gku1075 PMID: 25355519
6. Zhang N. et al., "The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals," (in eng), Dev Cell, vol. 19, no. 1, pp. 27–38, Jul 20 2010, https://doi.org/10.1016/j.devcel.2010.06.015 PMID: 20643348

7. Yin F., Yu J., Zheng Y., Chen Q., Zhang N., and Pan D., "Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2," (in Eng), Cell, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. vol. 154, no. 6, pp. 1342–55, Sep 12 2013, https://doi.org/10.1016/j.cell.2013.08.025 PMID: 24012335

8. Li W. et al., "Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus," (in Eng), Cancer Cell, Research Support, N.I.H., Extramural vol. 26, no. 1, pp. 48–60, Jul 14 2014, https://doi.org/10.1016/j.ccr.2014.05.001 PMID: 25026211

9. Ma S., Meng Z., Chen R., and Guan K.-L., "The Hippo Pathway: Biology and Pathophysiology," Annual Review of Biochemistry, vol. 88, no. 1, pp. 577–604, 2019, https://doi.org/10.1146/annurev-biochem-013118-111825 PMID: 30566373

10. Li W., Cooper J., Karajanni s M. A., and Giancotti F. G., "Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus," (in Eng), EMBO Rep, Feb 21 2012, https://doi.org/10.1038/embor.2012.11 PMID: 22482125

11. Gladden A. B., Hebert A. M., Schneeberger E. E., and McClatchey A. I., "The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex," (in eng), Dev Cell, vol. 19, no. 5, pp. 727–39, Nov 16 2010, https://doi.org/10.1016/j.devcel.2010.10.008 PMID: 21074722

12. Yi C. et al., "A tight junction-associated Merlin-angiomit complex mediates Merlin’s regulation of mitogenic signaling and tumor suppressive functions," (in eng), Cancer Cell, vol. 19, no. 4, pp. 527–40, Apr 12 2011, https://doi.org/10.1016/j.ccr.2011.02.017 PMID: 21481793

13. Bensener L. B., Barlan K., Rice S. E., Fehon R. G., and Gelfand V. I., "Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants," (in eng), Proc Natl Acad Sci U S A, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t vol. 107, no. 16, pp. 7311–6, Apr 20 2010, https://doi.org/10.1073/pnas.0907389107 PMID: 20368450

14. McClatchey A. I. and Giovannini M., "Membrane organization and tumorigenesis—the NF2 tumor suppressor, Merlin," (in eng), Genes Dev, vol. 19, no. 19, pp. 2265–77, Oct 1 2005, https://doi.org/10.1101/gad.1335605 PMID: 16204178

15. McCarty B. M. and Fehon R. G., "Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, Merlin," (in eng), The Journal of cell biology, Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S. vol. 133, no. 4, pp. 843–52, May 1996. [Online]. http://www.ncbi.nlm.nih.gov/pubmed/8666669. https://doi.org/10.1083/jcb.133.4.843 PMID: 8666669

16. Kressel M. and Schmucker B., "Nucleocytoplasmic transfer of the NF2 tumor suppressor protein Merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15," (in eng), Hum Mol Genet, vol. 11, no. 19, pp. 2269–78, Sep 15 2002. [Online]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12217955.

17. Muranen T., Gronholm M., Renkema G. H., and Carpen O., "Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor Merlin," (in eng), Oncogene, vol. 24, no. 7, pp. 1150–8, Feb 10 2005, https://doi.org/10.1038/sj.onc.1208283 PMID: 15580288

18. Gronholm M. et al., "A functional association between Merlin and HEI10, a cell cycle regulator," (in eng), Oncogene, Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. vol. 25, no. 32, pp. 4389–98, Jul 22 2006, https://doi.org/10.1038/sj.onc.1209475 PMID: 16532029

19. Li W. et al., "Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus," (in Eng), Cell, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t vol. 140, no. 4, pp. 477–90, Feb 19 2010, https://doi.org/10.1016/j.cell.2010.01.029 PMID: 20178741

20. Furukawa K. T., Yamashita K., Sakurai N., and Ohno S., "The Epithelial Circumferential Actin Belt Regulates YAP/TAZ through Nucleocytoplasmic Shuttling of Merlin," Cell Rep, vol. 20, no. 6, pp. 1435–447, Aug 8 2017, https://doi.org/10.1016/j.celrep.2017.07.032 PMID: 28793266

21. Adelman K. and Lis J. T., "Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans," (in eng), Nat Rev Genet, vol. 13, no. 10, pp. 720–31, Sep 18 2012, https://doi.org/10.1038/nrg3293 PMID: 22986266

22. Nechaev S. and Adelman K., "Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation," (in eng), Biochimica et biophysica acta, vol. 1809, no. 1, pp. 34–45, Jan 2011, https://doi.org/10.1016/j.bbagrm.2010.11.001 PMID: 21081187
Merlin/NF2 interacts with the PAF complex

23. Jonkers I. and Lis J. T., "Getting up to speed with transcription elongation by RNA polymerase II," (in Eng), Nat Rev Mol Cell Biol, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review vol. 16, no. 3, pp. 167–77, Mar 2015, https://doi.org/10.1038/nrm3953 PMID: 25893310

24. Petesch S. J. and Lis J. T., "Overcoming the nucleosome barrier during transcript elongation," (in eng), Trends Genet, vol. 28, no. 6, pp. 285–94, Jun 2012, https://doi.org/10.1016/j.tig.2012.02.005 PMID: 22465610

25. Jaehning J. A., "The Paf1 complex: platform or player in RNA polymerase II transcription?," (in eng), Biochimica et biophysica acta, vol. 1799, no. 5–6, pp. 379–88, May-Jun 2010, https://doi.org/10.1016/j.bbapap.2010.01.001 PMID: 20069042

26. Jo J. H., Chung T. M., Youn H., and Yoo J. Y., "Cytoplasmic paralbromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis," (in Eng), Nature communications, Research Support, Non-U.S. Gov’t vol. 5, p. 5433, Nov 12 2014, https://doi.org/10.1038/ncomms5433 PMID: 25388829

27. Yu M. et al., "RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II," (in Eng), Science, Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t vol. 350, no. 6266, pp. 1383–136, Dec 11 2015, https://doi.org/10.1126/science.aad2338 PMID: 26659056

28. Chen F. X. et al., "PAF1, a Molecular Regulator of Promoter-Proximal Pausing by RNA Polymerase II," (in Eng), Cell, Research Support, N.I.H., Extramural vol. 162, no. 5, pp. 1003–15, Aug 27 2015, https://doi.org/10.1016/j.cell.2015.07.042 PMID: 26279186

29. Yang Y. et al., "PAF Complex Plays Novel Subunit-Specific Roles in Alternative Cleavage and Polyadenylation," (in Eng), PLoS Genet, Research Support, N.I.H., Extramural vol. 12, no. 1, p. e1005794, Jan 2016, https://doi.org/10.1371/journal.pgen.1005794 PMID: 26715774

30. Newey P. J., Bowl M. R., Cranston T., and Thakker R. V., "Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors," (in eng), Human mutation, vol. 31, no. 3, pp. 295–307, Mar 2010, https://doi.org/10.1002/humu.21188 PMID: 20052758

31. Chaudhary K., Deb S., Moniaux N., Ponnumamy M. P., and Batra S. K., "Human RNA polymerase II-associated factor complex: dysregulation in cancer," (in eng), Oncogene, vol. 26, no. 54, pp. 7499–507, Nov 29 2007, https://doi.org/10.1038/sj.onc.1210582 PMID: 17599057

32. Gautier L., Cope L., Bolstad B. M., and Irizarry R. A., "affy—analysis of Affymetrix GeneChip data at the probe level," (in eng), Bioinformatics, Evaluation Studies Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. vol. 20, no. 3, pp. 307–15, Feb 12 2004, https://doi.org/10.1093/bioinformatics/btg405 PMID: 14960456

33. Smyth G. K., "Limma: linear models for microarray data," Bioinformatics and Computational Biology Solutions using R and Bioconductor, vol. Gentleman R., Carey V., Dudoit S., Irizarry R., Huber W. (eds). Springer, New York, pp. 397–420, 2005.

34. Anders S. and Huber W., "Differential expression analysis for sequence count data," (in eng), Genome biology, Research Support, Non-U.S. Gov’t vol. 11, no. 10, p. R106, 2010, https://doi.org/10.1186/gb-2010-11-10-r106 PMID: 20979621

35. S. N. Liu X., Nestler E., and Shen L., "ngs.plot: An easy-to-use visualization tool for global enrichment of next-generation sequencing data" (http://code.google.com/p/ngsplot/) no. New York, NY: Department of Neuroscience, Mount Sinai School of Medicine, 2012.

36. Rosenfeld J., Capdevielle J., Guillemot J. C., and Ferrara P., "In-gel digestion of proteins for internal protein identification strategies employing MS or MS/MS and database searching," (in eng), Anal Chem, vol. 71, no. 14, pp. 2871–82, Jul 15 1999, [Online]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10424174

37. Clauser K. R., Baker P., and Burlingame A. L., "Role of accurate mass measurement (+/- 1 ppm) in protein identification strategies employing MS or MS/MS and database searching," (in eng), Anal Chem, vol. 71, no. 14, pp. 2871–82, Jul 15 1999, [Online]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10424174

38. Huang da W., Sherman B. T., and Lempicki R. A., "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," (in eng), Nature protocols, Research Support, N.I.H., Extramural vol. 4, no. 1, pp. 44–57, 2009, https://doi.org/10.1038/nprot.2008.211 PMID: 19131956

39. Huang J. and Chen J., "VprBP targets Merlin to the Roc1-Cul4A-DBD1 E3 ligase complex for degradation," (in eng), Oncogene, vol. 27, no. 29, pp. 4056–64, Jul 3 2008, https://doi.org/10.1038/onc.2008.44 PMID: 18332868

40. Simic R. et al., "Chromatin remodeling protein Chd1 interacts with transcription elongation factors and localizes to transcribed genes," (in eng), The EMBO journal, vol. 22, no. 8, pp. 1846–56, Apr 15 2003, https://doi.org/10.1093/emboj/cdg179 PMID: 12682017
41. Fong Y. W. and Zhou Q., "Stimulatory effect of splicing factors on transcriptional elongation," (in eng), Nature, vol. 414, no. 6866, pp. 929–33, Dec 20–27 2001, https://doi.org/10.1038/414929a PMID: 11780068

42. Mann M., Zou Y., Chen Y., Brann D., and Vadlamudi R., "PELP1 oncogenic functions involve alternative splicing via PRMT6," (in eng), Molecular oncology, vol. 8, no. 2, pp. 389–400, Mar 2014, https://doi.org/10.1016/j.molonc.2013.12.012 PMID: 24447537

43. Chakravarty D., Tekmal R. R., and Vadlamudi R. K., "PELP1: A novel therapeutic target for hormonal cancers," (in eng), IUBMB Life, vol. 62, no. 3, pp. 162–9, Mar 2010, https://doi.org/10.1002/iub.287 PMID: 20014005

44. Kim J., Guermah M., and Roeder R. G., "The human PAF1 complex acts in chromatin transcription elongation both independently and cooperatively with SII/TFIIS," (in eng), Cell, vol. 140, no. 4, pp. 491–503, Feb 19 2010, https://doi.org/10.1016/j.cell.2009.12.050 PMID: 20178742

45. Lee W. H., "Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee," (in eng), Neurosurgery, vol. 27, no. 3, pp. 389–95; discussion 396, Sep 1990. [Online]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2234331

46. Iwata T., Muzisawa N., Taketani Y., Itakura M., and Yoshimoto K., "Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen," Oncogene, vol. 26, no. 42, pp. 6176–83, Sep 13 2007, https://doi.org/10.1038/sj.onc.1210445 PMID: 17404568

47. Cao Q. F. et al., "Characterization of the Human Transcription Elongation Factor Rtf1: Evidence for Nonoverlapping Functions of Rtf1 and the Pafl Complex," (in Eng), Mol Cell Biol, Research Support, Non-U.S. Gov’t vol. 35, no. 20, pp. 3459–70, Oct 2015, https://doi.org/10.1128/MCB.00601-15 PMID: 26217014

48. Mboogning J. et al., "The PAF complex and Prf1/Rtf1 delineate distinct Cdk9-dependent pathways regulating transcription elongation in fission yeast," (in Eng), PLoS Genet, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t vol. 9, no. 12, p. e1004029, 2013, https://doi.org/10.1371/journal.pgen.1004029 PMID: 24385927

49. Elenbaas B. et al., "Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells," Genes Dev, vol. 15, no. 1, pp. 50–65, 2001. [Online]. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7951231

50. Yang C. et al., "Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function," (in eng), Proc Natl Acad Sci U S A, vol. 108, no. 12, pp. 4980–5, Mar 22 2011, https://doi.org/10.1073/pnas.1102198102 PMID: 21383154

51. Sainz J., Huynh D. P., Figueroa K., Ragge N. K., Baser M. E., and Pulst S. M., "Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwanommas," (in eng), Hum Mol Genet, vol. 3, no. 6, pp. 885–91, Jun 1994. [Online]. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7951231

52. Rozenblatt-Rosen O. et al., "The parafibromin tumor suppressor protein is part of a human Pafl complex," (in eng), Mol Cell Biol, vol. 25, no. 2, pp. 612–20, Jan 2005, https://doi.org/10.1128/MCB.25.2.612-620.2005 PMID: 15632063

53. Panicker L. M., Zhang J. H., Dagur P. K., Gastinger M. J., and Simonds W. F., "Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome," (in eng), Endocr Relat Cancer, vol. 17, no. 2, pp. 513–24, Jun 2010, https://doi.org/10.1007/ERC-09-0272 PMID: 20304979

54. Bradley K. J. et al., "Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours," (in eng), Clinical endocrinology, vol. 64, no. 3, pp. 299–306, Mar 2006, https://doi.org/10.1111/j.1365-2265.2006.02460.x PMID: 16487440

55. Ahronowitz I., Xin W., Kiely R., Sims K., MacCollin M., and Nunes F. P., "Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings," (in eng), Human mutation, vol. 28, no. 1, pp. 1–12, Jan 2007, https://doi.org/10.1002/humu.20393 PMID: 16983642

56. Weinstein I. B., "Cancer. Addiction to oncogenes—the Achilles heal of cancer," (in eng), Science, vol. 297, no. 5578, pp. 63–4, Jul 5 2002, PMID: 12098689

57. Subramanian A. et al., "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles," (in eng), Proc Natl Acad Sci U S A, vol. 102, no. 43, pp. 15545–50, Oct 25 2005, https://doi.org/10.1073/pnas.0506580102 PMID: 16199517

58. Garnett M. J. et al., "Systematic identification of genomic markers of drug sensitivity in cancer cells," (in eng), Nature, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t vol. 483, no. 7391, pp. 570–5, Mar 29 2012, https://doi.org/10.1038/nature11005 PMID: 22460902
59. Chen Y. et al., "DSIF, the Paf1 complex, and Tat-SF1 have nonredundant, cooperative roles in RNA polymerase II elongation," (in eng), *Genes Dev*, vol. 23, no. 23, pp. 2765–77, Dec 1 2009, https://doi.org/10.1101/gad.1834709 PMID: 19952111

60. Morris L. G. et al., "Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation," (in Eng), *Nat Genet*, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't vol. 45, no. 3, pp. 253–61, Mar 2013, https://doi.org/10.1038/ng.2358 PMID: 23354438

61. Sims R. J. 3rd et al., "Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing," (in eng), *Mol Cell*, vol. 28, no. 4, pp. 665–76, Nov 30 2007, https://doi.org/10.1016/j.molcel.2007.11.010 PMID: 18042460

62. Sadeqzadeh E., de Bock C. E., and Thorne R. F., "Sleeping giants: emerging roles for the fat cadherins in health and disease," (in Eng), *Medicinal research reviews*, Review vol. 34, no. 1, pp. 190–221, Jan 2014, https://doi.org/10.1002/med.21286 PMID: 23720094

63. Grasso C. S. et al., "The mutational landscape of lethal castration-resistant prostate cancer," (in eng), *Nature*, vol. 487, no. 7406, pp. 239–43, Jul 12 2012, https://doi.org/10.1038/nature11125 PMID: 22728289

64. Huang S., Guizar Z. G., Salari K., Lapointe J., Brooks J. D., and Pollack J. R., "Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness," (in eng), *Oncogene*, vol. 31, no. 37, pp. 4164–70, Sep 13 2012, https://doi.org/10.1038/onc.2011.590 PMID: 22179824

65. Liu W. et al., "Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer," (in eng), *Oncogene*, vol. 31, no. 35, pp. 3939–48, Aug 30 2012, https://doi.org/10.1038/onc.2011.554 PMID: 22139082

66. Escobar-Hoyos L., Knorr K., and Abdel-Waha b O., "Aberrant RNA Splicing in Cancer," *Annual Review of Cancer Biology*, vol. 3, no. 1, pp. 167–185, 2019, https://doi.org/10.1146/annurev-cancerbio-030617-050407 PMID: 32864546

67. Feng Y. and Irvine K. D., "Processing and phosphorylation of the Fat receptor," (in Eng), *Proc Natl Acad Sci U S A*, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't vol. 106, no. 29, pp. 11989–94, Jul 21 2009, https://doi.org/10.1073/pnas.0811540106 PMID: 19574458

68. Magg T., Schreiner D., Solis G. P., Bade E. G., and Hofer H. W., "Processing of the human protocadherin Fat1 and translocation of its cytoplasmic domain to the nucleus," (in Eng), *Experimental cell research*, Research Support, Non-U.S. Gov't vol. 307, no. 1, pp. 100–8, Jul 1 2005, https://doi.org/10.1016/j.yexcr.2005.03.006 PMID: 15922730

69. Sadeqzadeh E. et al., "Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products," (in eng), *J Biol Chem*, Research Support, Non-U.S. Gov't vol. 286, no. 32, pp. 28181–91, Aug 12 2011, https://doi.org/10.1074/jbc.M111.234419 PMID: 21680732

70. Fanto M. et al., "The tumor-suppressor and cell adhesion molecule Fat controls planar polarity via physical interactions with Atrophin, a transcriptional corepressor," (in Eng), *Development*, Research Support, Non-U.S. Gov't vol. 130, no. 4, pp. 763–74, Feb 2003. [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/12506006

71. Hou R. and Sibinga N. E., "Atrophin proteins interact with the Fat1 cadherin and regulate migration and orientation in vascular smooth muscle cells," (in Eng), *J Biol Chem*, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't vol. 284, no. 11, pp. 6955–65, Mar 13 2009, https://doi.org/10.1074/jbc.M809333200 PMID: 19131340

72. Kikuchi I. et al., "Dephosphorylated parafibromin is a transcriptional coactivator of the Wnt/Hedgehog/Notch pathways," *Nature communications*, vol. 7, p. 12887, Sep 21 2016, https://doi.org/10.1038/ncomms12887 PMID: 27650679

73. Agarwal S. K., Simonds W. F., and Marx S. J., "The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3," (in eng), *Molecular cancer*, vol. 7, p. 65, 2008, https://doi.org/10.1186/1476-4598-7-65 PMID: 18686124

74. Lee H. Y. et al., "FAT1 mutations cause a glomerulotubular nephropathy," (in Eng), *Nature communications*, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't vol. 7, p. 10822, Feb 24 2016, https://doi.org/10.1038/ncomms10822 PMID: 26905694

75. Ciani L., Patel A., Allen N. D., and Frenche-Constant C., "Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype," (in Eng), *Mol Cell Biol*, Research Support, Non-U.S. Gov't vol. 23, no. 10, pp. 3575–82, May 2003. [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/12724416

76. M. A. Jackson, T. A. Rich, M. I. Hu, N. D. Perrier, and S. G. Waguespack, "CDC73-Related Disorders," in *GeneReviews(R)*, R. A. Pagon et al. Eds. Seattle (WA), 1999.

77. Sobhian B. et al., "HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP," (in eng), *Mol Cell*, vol. 38, no. 3, pp. 439–51, May 14 2010, https://doi.org/10.1016/j.molcel.2010.04.012 PMID: 20471949
78. Gallastegui E., Millan-Zambrano G., Terme J. M., Chavez S., and Jordan A., "Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency," (in eng), *J Virol*, vol. 85, no. 7, pp. 3187–202, Apr 2011, https://doi.org/10.1128/JVI.01920-10 PMID: 21270164

79. Vanti M. et al., "Yeast genetic analysis reveals the involvement of chromatin reassembly factors in repressing HIV-1 basal transcription," (in eng), *PLoS Genet*, vol. 5, no. 1, p. e1000339, Jan 2009, https://doi.org/10.1371/journal.pgen.1000339 PMID: 19148280